The therapeutic potential of tacrine
Tacrine, a non-competitive inhibitor of acetylcholine esterase, has been approved for the treatment of patients with mild to moderate Alzheimer’s disease in 1995. The available evidence suggests that in a substantial proportion of patients tacrine has the potential to improve cognitive functions, to ameliorate behavioural problems, and to delay the time to significant clinical endpoints. Thus, tacrine meets realistic expectations from symptomatic treatment. The major safety concern about tacrine is the probability of liver enzyme elevations and the high frequency of adverse events, particularly gastrointestinal. Findings are presented from an open-label multicentre study showing that tacrine is a safe and manageable compound in private practice.
KeywordsLiver Enzyme Elevation Nursing Home Admission Major Safety Concern Aberrant Motor Behaviour Progressive Deterioration Scale
Unable to display preview. Download preview PDF.
- American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed, rev. American Psychiatric Association, WashingtonGoogle Scholar
- De Jong R, Ostersund OW, Roy GW (1989) Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 11: 545–554Google Scholar
- Erzigkeit H (1989) SKT. Ein Kurztest zur Erfassung von Gedächtnis- und Aufmerksamkeitsstörungen. Beltz, WeinheimGoogle Scholar
- Gutzmann H, Hadler D, Erzigkeit H (1997) Long-term treatment of Alzheimer’s disease with idebenone. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (eds) Alzheimer’s disease: biology, diagnosis and therapeutics. Wiley, New York, pp 688–705Google Scholar